Physician profile
Stacey Lynn Roberts
NPI 1831656230
$2,928.27
in general payments reported to CMS, 2019-2025
28 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.37 · 2022: $755 · 2023: $69.17 · 2024: $56.31 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110 · Education: $39.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,109.50 |
| Education | $39.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $801.85 | 2022-2023 | Intellis Adaptivestim |
| Abbvie INC. | $341.85 | 2025 | |
| Jazz Pharmaceuticals INC. | $303.52 | 2025 | |
| Axsome Therapeutics, INC. | $281.40 | 2025 | Symbravo, Sunosi |
| Otsuka America Pharmaceutical, INC. | $150.43 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $144.53 | 2025 | Austedo Xr, Ajovy |
| Livanova USA, INC. | $96.09 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurocrine Biosciences, INC. | $94.52 | 2025 | |
| Vanda Pharmaceuticals INC. | $89.82 | 2025 | Ponvory |
| Sk Life Science, INC. | $88.74 | 2025 | |
| Harmony Biosciences LLC | $80.78 | 2025 | |
| Lundbeck LLC | $63.87 | 2025 | Vyepti |
| Abiomed | $56.31 | 2024 | Impella |
| Amgen INC. | $45.44 | 2025 | Uplizna |
| Ucb, INC. | $35.93 | 2025 | Zilbrysq, Rystiggo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $32.52 | 2025 | |
| Cycle Pharmaceuticals INC | $25.51 | 2025 | Bafiertam |
| Avanir Pharmaceuticals, INC. | $23.37 | 2021 | |
| Zimmer Biomet Holdings, INC. | $22.73 | 2023 | Ti Rapidflap Spindown |
| Averitas Pharma INC. | $21.06 | 2025 | Qutenza |
| Astrazeneca Pharmaceuticals Lp | $20.00 | 2025 | Wainua |
| Azurity Pharmaceuticals, INC. | $18.46 | 2025 | Horizant |
| Alexion Pharmaceuticals, INC. | $18.27 | 2025 | Ultomiris |
| Octapharma USA, INC. | $18.24 | 2025 | Panzyga |
| Vertex Pharmaceuticals Incorporated | $16.71 | 2025 | |
| Lilly USA, LLC | $15.89 | 2025 | Kisunla |
| Argenx US, INC. | $14.61 | 2025 | Vyvgart Hytrulo |
| Spr Therapeutics, INC | $5.82 | 2025 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.